ERBB2 and cancer: Furthermore, unlike previous studies by Du et al. [40] that did not differentiate between HER2-positive and HER2-low cancers as done in Task 2 of this study, our approach helps inform potential HER2-targeted therapy decisions by applying quantitative PA imaging methods.